Synmosa Biopharma Statistics
Total Valuation
Synmosa Biopharma has a market cap or net worth of TWD 16.11 billion. The enterprise value is 18.09 billion.
Market Cap | 16.11B |
Enterprise Value | 18.09B |
Important Dates
The next estimated earnings date is Monday, November 11, 2024.
Earnings Date | Nov 11, 2024 |
Ex-Dividend Date | Aug 9, 2024 |
Share Statistics
Synmosa Biopharma has 424.62 million shares outstanding. The number of shares has increased by 7.65% in one year.
Shares Outstanding | 424.62M |
Shares Change (YoY) | +7.65% |
Shares Change (QoQ) | -0.14% |
Owned by Insiders (%) | 8.82% |
Owned by Institutions (%) | 5.59% |
Float | 354.78M |
Valuation Ratios
The trailing PE ratio is 23.24 and the forward PE ratio is 17.73.
PE Ratio | 23.24 |
Forward PE | 17.73 |
PS Ratio | 3.08 |
PB Ratio | 2.31 |
P/FCF Ratio | 61.59 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.21, with an EV/FCF ratio of 69.14.
EV / Earnings | 26.25 |
EV / Sales | 3.49 |
EV / EBITDA | 18.21 |
EV / EBIT | 27.56 |
EV / FCF | 69.14 |
Financial Position
The company has a current ratio of 2.22, with a Debt / Equity ratio of 30.48.
Current Ratio | 2.22 |
Quick Ratio | 1.42 |
Debt / Equity | 30.48 |
Debt / EBITDA | 2.49 |
Debt / FCF | 9.57 |
Interest Coverage | 11.31 |
Financial Efficiency
Return on equity (ROE) is 6.21% and return on invested capital (ROIC) is 3.83%.
Return on Equity (ROE) | 6.21% |
Return on Assets (ROA) | 3.39% |
Return on Capital (ROIC) | 3.83% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.42 |
Inventory Turnover | 1.87 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.45% in the last 52 weeks. The beta is 0.27, so Synmosa Biopharma's price volatility has been lower than the market average.
Beta (5Y) | 0.27 |
52-Week Price Change | +13.45% |
50-Day Moving Average | 37.09 |
200-Day Moving Average | 36.03 |
Relative Strength Index (RSI) | 56.44 |
Average Volume (20 Days) | 665,848 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Synmosa Biopharma had revenue of TWD 5.19 billion and earned 689.09 million in profits. Earnings per share was 1.63.
Revenue | 5.19B |
Gross Profit | 2.20B |
Operating Income | 668.16M |
Pretax Income | 670.01M |
Net Income | 689.09M |
EBITDA | 980.74M |
EBIT | 668.16M |
Earnings Per Share (EPS) | 1.63 |
Balance Sheet
The company has 1.83 billion in cash and 2.50 billion in debt, giving a net cash position of -673.58 million or -1.59 per share.
Cash & Cash Equivalents | 1.83B |
Total Debt | 2.50B |
Net Cash | -673.58M |
Net Cash Per Share | -1.59 |
Equity (Book Value) | 8.22B |
Book Value Per Share | 16.46 |
Working Capital | 2.65B |
Cash Flow
In the last 12 months, operating cash flow was 531.15 million and capital expenditures -269.52 million, giving a free cash flow of 261.63 million.
Operating Cash Flow | 531.15M |
Capital Expenditures | -269.52M |
Free Cash Flow | 261.63M |
FCF Per Share | 0.62 |
Margins
Gross margin is 42.48%, with operating and profit margins of 12.88% and 13.29%.
Gross Margin | 42.48% |
Operating Margin | 12.88% |
Pretax Margin | 12.92% |
Profit Margin | 13.29% |
EBITDA Margin | 18.91% |
EBIT Margin | 12.88% |
FCF Margin | 5.05% |
Dividends & Yields
This stock pays an annual dividend of 0.55, which amounts to a dividend yield of 1.45%.
Dividend Per Share | 0.55 |
Dividend Yield | 1.45% |
Dividend Growth (YoY) | 18.41% |
Years of Dividend Growth | 3 |
Payout Ratio | 28.22% |
Buyback Yield | -7.65% |
Shareholder Yield | -6.20% |
Earnings Yield | 4.30% |
FCF Yield | 1.62% |
Stock Splits
The last stock split was on August 9, 2024. It was a forward split with a ratio of 1.1.
Last Split Date | Aug 9, 2024 |
Split Type | Forward |
Split Ratio | 1.1 |